Numaferm GmbH
About us
About Numaferm
Founded in 2009 at Heinrich Heine University in Düsseldorf, Numaferm GmbH is a leading biotechnology company specializing in the recombinant production of peptides and proteins. With over 30 highly skilled employees and a state-of-the-art facility exceeding 1,000 sqm in Düsseldorf, we provide solutions that guarantee maximum efficiency, scalability, and sustainability.
Technology & Innovation
At the core of our operations is the proprietary Numaswitch technology platform. This innovation enables fast, cost-effective, and sustainable production of biomolecules in large quantities and exceptional purity – within just a few weeks. Our focus lies particularly on "pepteins" (peptides & proteins) ranging from 2 to 600 amino acids.
Applications
Numaferm serves a diverse range of clients across the pharmaceutical, agricultural, veterinary, generics, and cosmetics industries. Our products are widely applied in drug discovery, diagnostics, and as the foundation for innovative therapeutic approaches.
Our Mission
At Numaferm, quality, innovation, and sustainability are our top priorities. Our mission is to deliver tailored solutions that meet our customers’ specific needs. With our expertise, we are setting new standards in biochemical production and actively contributing to advancements in science and industry.
Visit Us
Learn more about our innovative technologies and discover how Numaferm can support your projects. We look forward to connecting with you!
Contact
Numaferm GmbH
Email: info@numaferm.com
Address
Merowingerplatz 1a
40225 Düsseldorf
Germany
E-mail: info@numaferm.com
Phone: +49 211 97532900
Internet: numaferm.com/
Contact person:
Dr. Christian Schwarz
Chief Scientific Officer (CSO)
E-mail: christian.schwarz@numaferm.com
Phone: +49 160 8385834
Dr. Roland Hecht
Chief Executive Officer (CEO)
E-mail: roland.hecht@numaferm.com
Phone: +49 160 94738924
Products & Services
Numaferm provides a biochemical production platform for the easy and efficient synthesis of peptides and proteins. This novel technology is called Numaswitch. Target proteins are genetically fused to Switchtag libraries, promoting high-titer production of fusion proteins within E. coli cells as inclusion bodies. Switchtags play a crucial role in facilitating the efficient refolding of fusion proteins, while the unique Numacut TEV protease removes the Switchtag from the targets in a traceless manner. Evolved through artificial intelligence and directed evolution approaches, the Numacut TEV protease demonstrates expanded substrate tolerance compared to the wild type enzyme, allowing the release of targets with native N-termini. Numaswitch addresses the challenge of low refolding efficiencies in inclusion body methods, enabling high product yields and purities. Production of these molecules is accomplished within weeks and in an environmentally sustainable manner, highlighting the technology's advantages.
Numacut TEV Protease
The Numacut TEV protease is an improved variant of the Tobacco Etch Virus (TEV) protease with broadened substrate tolerance in comparison to the wild type enzyme. Evolved by artificial intelligence and directed evolution approaches, the recognition site of the TEV protease (ENLYFQ/S) was broadened to ENLYFQ/X (X: any amino acid, except P). Fusion proteins featuring the ENLYFQ sequence are efficiently cleaved between Q and X releasing N-terminal native target peptides or proteins.
Numaswitch Technology
Numaswitch is a biochemical production platform for easy and efficient peptide and protein production. Target proteins are fused to Switchtags which promote the high-titer production within E. coli cells as inclusion bodies. Switchtags trigger the efficient refolding of fusion proteins, while the Numacut TEV protease removes the desired targets tracelessly from the Switchtag. This technology resolves the challenge of low refolding efficiencies resulting in high product yields and purities.
